The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2025

Filed:

Mar. 12, 2021
Applicants:

The Johns Hopkins University, Baltimore, MD (US);

Capricor, Inc., Beverly Hills, CA (US);

Inventors:

Stephen John Gould, Baltimore, MD (US);

Linda Marban, Santa Monica, CA (US);

Tariq Hussain Warsi, Thousand Oaks, CA (US);

Assignees:

The Johns Hopkins University, Baltimore, MD (US);

Capricor, Inc., Beverly Hills, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 9/127 (2006.01); A61K 31/7105 (2006.01); A61K 35/28 (2015.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); C07K 14/245 (2006.01); C12N 9/06 (2006.01); C12N 15/85 (2006.01); C12N 15/88 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 9/127 (2013.01); A61K 31/7105 (2013.01); A61K 35/28 (2013.01); A61P 31/14 (2018.01); C07K 14/245 (2013.01); C12N 9/003 (2013.01); C12N 15/85 (2013.01); C12N 15/88 (2013.01); A61K 2039/53 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C12N 2800/107 (2013.01); C12N 2830/002 (2013.01); C12N 2840/10 (2013.01);
Abstract

The present invention relates to modular systems for vaccination against infectious agents that involves the delivery of, e.g., exosome-loaded, antigen-encoding mRNAs to and into cells and tissues of the immunized subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of vaccines, e.g., nucleic acid vaccines, loaded into extracellular vesicles, e.g., exosomes loaded with synthetic mRNAs encoding multiple surface and cytoplasmic antigens of interest, e.g., antigenic polypeptides derived from an infectious virus, e.g., SARS-CoV-2, designed to elicit strong humoral and cellular immune responses due to the simultaneous expression of antigens in their native state and as exosome-associated antigens.


Find Patent Forward Citations

Loading…